A

+ Watchlist + Portfolio

Agilent Technologies, Inc.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $166.68
52-Week Range: $108.35 – $177.05
Market Cap: $47.30B
P/E (TTM): 33.09
EPS (TTM): 5.07
Dividend Yield: 0.61%

Advanced Metrics

Price/Book: 6.43
PEG Ratio: 1.39
Return on Equity: 20.97%
Return on Assets: 8.63%
Gross Margin: 53.65%
Operating Margin: 25.56%
Profit Margin: 19.53%
Current Ratio: 2.05
Debt/Equity: 0.56
Total Debt: $4.15B
Free Cash Flow: $1.06B
Revenue Growth: 8.10%
Earnings Growth: 8.50%
Enterprise Value: $49.69B

A Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$6.85B	$6.83B	$6.51B	$6.95B
Cost of Revenue	$3.13B	$3.37B	$2.98B	$3.31B
Gross Profit	$3.72B	$3.46B	$3.54B	$3.64B
Research & Development	$467.00M	$481.00M	$479.00M	$455.00M
Selling, General & Admin	$1.64B	$1.63B	$1.57B	$1.71B
Operating Expenses	$2.10B	$2.12B	$2.05B	$2.16B
Operating Income	$1.62B	$1.35B	$1.49B	$1.48B
EBITDA	$1.91B	$1.71B	$1.87B	$1.83B
Pretax Income	$1.50B	$1.34B	$1.52B	$1.44B
Income Tax	$250.00M	$99.00M	$232.00M	$132.00M
Net Income	$1.25B	$1.24B	$1.29B	$1.30B
Diluted EPS	4.18	4.19	4.43	4.57
Diluted Shares	300.00M	296.00M	291.00M	285.00M

A Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$1.05B	$1.59B	$1.33B	$1.79B
Receivables	$1.41B	$1.29B	$1.32B	$1.49B
Inventory	$1.04B	$1.03B	$972.00M	$1.02B
Current Assets	$3.78B	$4.19B	$3.96B	$4.59B
Total Assets	$10.53B	$10.76B	$11.85B	$12.73B
Current Liabilities	$1.86B	$1.60B	$1.90B	$2.35B
Long-Term Debt	$2.73B	$2.73B	$3.35B	$3.05B
Total Debt	$2.77B	$2.73B	$3.39B	$3.35B
Total Liabilities	$5.23B	$4.92B	$5.95B	$5.99B
Retained Earnings	$324.00M	$782.00M	$750.00M	$1.39B
Shareholders' Equity	$5.30B	$5.84B	$5.90B	$6.74B
Working Capital	$1.92B	$2.58B	$2.06B	$2.25B
Net Debt	$1.72B	$1.15B	$2.06B	$1.56B

A Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$1.31B	$1.77B	$1.75B	$1.56B
Capital Expenditure	-$291.00M	-$298.00M	-$378.00M	-$407.00M
Free Cash Flow	$1.02B	$1.47B	$1.37B	$1.15B
Depreciation & Amortisation	$317.00M	$271.00M	$257.00M	$288.00M
Stock-Based Compensation	$125.00M	$111.00M	$129.00M	$128.00M
Investing Cash Flow	-$338.00M	-$310.00M	-$1.26B	-$394.00M
Financing Cash Flow	-$1.37B	-$930.00M	-$752.00M	-$715.00M
Dividends Paid	-$250.00M	-$265.00M	-$274.00M	-$282.00M
Share Repurchases	-$1.14B	-$575.00M	-$1.15B	-$425.00M
Net Change in Cash	-$398.00M	$532.00M	-$259.00M	$450.00M

A Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Revenue	$1.67B	$1.74B	$1.86B	$1.80B	$1.83B	$1.88B
Cost of Revenue	$802.00M	$850.00M	$871.00M	$852.00M	$845.00M	$836.00M
Gross Profit	$866.00M	$888.00M	$990.00M	$946.00M	$990.00M	$1.04B
Research & Development	$112.00M	$111.00M	$119.00M	$117.00M	$126.00M	$123.00M
Selling, General & Admin	$454.00M	$417.00M	$428.00M	$476.00M	$465.00M	$475.00M
Operating Expenses	$566.00M	$528.00M	$547.00M	$593.00M	$591.00M	$598.00M
Operating Income	$300.00M	$360.00M	$443.00M	$353.00M	$399.00M	$444.00M
EBITDA	$362.00M	$466.00M	$540.00M	$456.00M	$500.00M	$539.00M
Pretax Income	$260.00M	$366.00M	$442.00M	$364.00M	$408.00M	$444.00M
Income Tax	$45.00M	$30.00M	$8.00M	$59.00M	$69.00M	$82.00M
Net Income	$215.00M	$336.00M	$434.00M	$305.00M	$339.00M	$362.00M
Diluted EPS	0.75	1.18	1.53	1.07	1.20	1.28
Diluted Shares	285.00M	285.00M	284.00M	284.00M	283.00M	283.00M

A Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Cash & Equivalents	$1.49B	$1.53B	$1.79B	$1.76B	$1.81B	$1.76B
Receivables	$1.37B	$1.38B	$1.49B	$1.52B	$1.50B	$1.48B
Inventory	$991.00M	$1.01B	$1.02B	$1.06B	$1.09B	$1.12B
Current Assets	$4.21B	$4.25B	$4.59B	$4.62B	$4.76B	$4.69B
Total Assets	$12.16B	$12.23B	$12.73B	$12.81B	$13.06B	$13.97B
Current Liabilities	$2.01B	$1.89B	$2.35B	$2.23B	$2.27B	$2.29B
Long-Term Debt	$3.35B	$3.35B	$3.05B	$3.05B	$3.05B	$3.65B
Total Debt	$3.50B	$3.41B	$3.35B	$3.35B	$3.35B	$3.95B
Total Liabilities	$6.02B	$5.86B	$5.99B	$5.91B	$5.94B	$6.60B
Retained Earnings	$912.00M	$1.10B	$1.39B	$1.48B	$1.69B	$1.91B
Shareholders' Equity	$6.14B	$6.37B	$6.74B	$6.91B	$7.12B	$7.36B
Working Capital	$2.20B	$2.36B	$2.25B	$2.38B	$2.49B	$2.40B
Net Debt	$2.01B	$1.87B	$1.56B	$1.60B	$1.55B	$2.19B

A Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Operating Cash Flow	$221.00M	$362.00M	$545.00M	$268.00M	$277.00M	$519.00M
Capital Expenditure	-$114.00M	-$103.00M	-$93.00M	-$93.00M	-$76.00M	-$80.00M
Free Cash Flow	$107.00M	$259.00M	$452.00M	$175.00M	$201.00M	$439.00M
Depreciation & Amortisation	$73.00M	$72.00M	$71.00M	$67.00M	$67.00M	$66.00M
Stock-Based Compensation	$30.00M	$32.00M	$26.00M	$41.00M	$32.00M	$32.00M
Investing Cash Flow	-$114.00M	-$96.00M	-$90.00M	-$93.00M	-$77.00M	-$1.03B
Financing Cash Flow	-$116.00M	-$219.00M	-$200.00M	-$222.00M	-$144.00M	$471.00M
Dividends Paid	-$70.00M	-$71.00M	-$70.00M	-$72.00M	-$72.00M	-$72.00M
Share Repurchases	-$165.00M	-$85.00M	-$85.00M	-$152.00M	-$65.00M	-$78.00M
Net Change in Cash	-$9.00M	$47.00M	$255.00M	-$47.00M	$56.00M	-$42.00M

Market Snapshot

About

Agilent Technologies, Inc. is a global leader in life sciences, diagnostics, and applied chemical markets. The company provides laboratory instruments, software, services, and consumables for the entire laboratory workflow. Agilent's products are used by pharmaceutical, biotechnology, academic, government, and industrial customers worldwide. The company operates through three segments: Life Sciences and Applied Markets (analytical instruments for drug discovery and quality assurance), Diagnostics and Genomics (pathology solutions and genomic analysis tools), and Agilent CrossLab (laboratory services and consumables). Founded in 1999 as a spin-off from Hewlett-Packard, Agilent is headquartered in Santa Clara, California. The company has built a strong portfolio through strategic acquisitions and organic innovation, serving scientists and researchers who rely on precision measurement and data analysis to advance healthcare, protect the environment, and ensure product quality.